Wuhan Hiteck Biological Pharma Co.,Ltd (300683.SZ)
300683.SZ Stock Price Chart
Explore Wuhan Hiteck Biological Pharma Co.,Ltd interactive price chart. Choose custom timeframes to analyze 300683.SZ price movements and trends.
300683.SZ Company Profile
Discover essential business fundamentals and corporate details for Wuhan Hiteck Biological Pharma Co.,Ltd (300683.SZ) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
8 Aug 2017
Employees
1.52K
Website
https://www.hiteck.com.cnCEO
Ya Chen
Description
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Jinlujie, a mouse nerve growth factor for injection; omeprazole sodium for injection; cyclic adenosine phosphate; Xinye, an acyclovir dispensable tablets; Bingbing Horse & Dragon, an indomethacin furazolidone suppository drug; Xunkeyuan, a tinidazole suppository drug; and Shufu, a nimodipine sustained release tablets. The company also provides measles virus and rubella virus nucleic acid detection kit; mycoplasma isolation and identification kit and culture tube; bacterial vaginosis rapid detection kit; measles virus IgG antibody detection kit; and coronavirus N-protein detection kit. In addition, it offers Lopinavir and Ritonavir APIs; and intermediates. The company offers its products in the field of nervous system and oncology. Wuhan Hiteck Biological Pharma Co.,Ltd was founded in 1992 and is based in Wuhan, China.
300683.SZ Financial Timeline
Browse a chronological timeline of Wuhan Hiteck Biological Pharma Co.,Ltd corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 16 May 2025
EPS came in at -¥0.23 , while revenue for the quarter reached ¥197.98M .
Earnings released on 31 Mar 2025
EPS came in at -¥0.11 , while revenue for the quarter reached ¥156.67M .
Dividend declared on 9 Jan 2025
A dividend of ¥0.13 per share was announced, adjusted to ¥0.13. The dividend was paid on 9 Jan 2025.
Earnings released on 29 Sept 2024
EPS came in at -¥0.13 , while revenue for the quarter reached ¥166.37M .
Earnings released on 29 Jun 2024
EPS came in at -¥0.05 , while revenue for the quarter reached ¥150.78M .
Earnings released on 16 May 2024
EPS came in at -¥0.72 , while revenue for the quarter reached ¥163.86M .
Earnings released on 31 Mar 2024
EPS came in at -¥0.13 , while revenue for the quarter reached ¥131.89M .
Earnings released on 30 Sept 2023
EPS came in at -¥0.12 , while revenue for the quarter reached ¥151.98M .
Earnings released on 30 Jun 2023
EPS came in at -¥0.07 , while revenue for the quarter reached ¥147.81M .
Earnings released on 31 Mar 2023
EPS came in at -¥0.01 , while revenue for the quarter reached ¥138.64M .
Earnings released on 1 Jan 2023
EPS came in at -¥0.25 , while revenue for the quarter reached ¥141.99M .
Earnings released on 30 Sept 2022
EPS came in at -¥0.00 , while revenue for the quarter reached ¥159.41M .
Earnings released on 30 Jun 2022
EPS came in at ¥0.09 , while revenue for the quarter reached ¥221.03M .
Earnings released on 31 Mar 2022
EPS came in at ¥0.06 , while revenue for the quarter reached ¥166.20M .
Earnings released on 31 Dec 2021
EPS came in at ¥0.07 , while revenue for the quarter reached ¥222.31M .
Earnings released on 30 Sept 2021
EPS came in at ¥0.11 , while revenue for the quarter reached ¥166.83M .
Earnings released on 30 Jun 2021
EPS came in at -¥0.07 , while revenue for the quarter reached ¥67.72M .
Earnings released on 23 Apr 2021
EPS came in at -¥0.14 , while revenue for the quarter reached ¥175.53M .
Earnings released on 31 Mar 2021
EPS came in at ¥0.14 , while revenue for the quarter reached ¥157.83M .
Earnings released on 30 Sept 2020
EPS came in at -¥0.07 , while revenue for the quarter reached ¥156.25M .
300683.SZ Stock Performance
Access detailed 300683.SZ performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.